
Nexien BioPharma, Inc. Share · US65343D1000 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Nexien BioPharma, Inc.
No Price
Closing Price OTC 30.04.2026:
0,0001 USD
30.04.2026 20:00
Current Prices from Nexien BioPharma, Inc.
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
UTC |
NXEN
|
USD
|
30.04.2026 20:00
|
0,0001 USD
| 0,00 USD |
Company Profile for Nexien BioPharma, Inc. Share
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
Company Data
Name Nexien BioPharma, Inc.
Company Nexien BioPharma, Inc.
Website
https://www.nexienbiopharma.com
Primary Exchange
UTC
ISIN US65343D1000
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Richard S. Greenberg
Country United States of America
Currency USD
Employees -
Address 4340 East Kentucky Avenue, 80246 Glendale
IPO Date 2017-11-29
Stock Splits
| Date | Split |
|---|---|
| 29.11.2017 | 1:6 |
| 22.07.1999 | 1:3 |
| 03.04.1995 | 1:2 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | NXEN |
More Shares
Investors who hold Nexien BioPharma, Inc. also have the following shares in their portfolio:

